Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age - GuruFocus.com

6/27/2022 12:00:00 AM2 years 10 months ago

Value Investing | Market insights and news of the investment gurus. Value investing screens and valuation tools.

  • In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group
  • Three 3-µg doses had favorable safety profile similar to place… [+30840 chars]

    full article...